Group 1 - The National Healthcare Security Administration released the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog [1] - Innovent Biologics has seven innovative products successfully included in the new medical insurance catalog, including the PD-1 inhibitor, Tyvyt (sintilimab injection), which has a new indication for advanced endometrial cancer [1][2] - Tyvyt is the only PD-1 inhibitor in its treatment area to be included in the medical insurance catalog, and it has been approved for eight indications since its launch in 2018, covering various cancers [1] Group 2 - Another innovative drug included in the new medical insurance catalog is IBI302 (teprotumumab), which is the first IGF-1R antibody drug approved in China and the second globally, marking a significant advancement in the treatment of thyroid eye disease [2] - Other innovative drugs added to the catalog target prevalent diseases such as lung cancer and hematological malignancies, including drugs like IBI308 (lazertinib), IBI310 (entrectinib), and IBI311 (ibrutinib) [2] - The inclusion of innovative drugs in the medical insurance catalog is a crucial step towards making these treatments accessible and affordable for more patients in China [2]

Core Viewpoint - Innovent Biologics has successfully included seven innovative products in the new National Medical Insurance Drug List (2025), which will be implemented on January 1, 2026 [1] Group 1: Product Inclusion - The seven innovative products included are: - Daboshu® (sintilimab injection, anti-PD-1 monoclonal antibody) with new indications - Xinbimin® (tremelimumab N01 injection, anti-IGF-1R monoclonal antibody) - Aoyixin® (leratinib tablets, EGFR TKI) - Dabote® (furazolidone tablets, KRAS G12C inhibitor) - Dabolet® (dihydroartemisinin capsules, ROS1 TKI) - Ruituo® (sepafitinib capsules, RET inhibitor) - Jiepalin® (pembrolizumab tablets, BTK inhibitor) [1] Group 2: Implementation Timeline - The new National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]

Core Insights - The company Innovent Biologics has successfully included seven innovative products in the newly released 2025 National Medical Insurance Directory, which includes the PD-1 inhibitor, Tyvyt® (sintilimab injection) and other mature products with expanded indications [1] Group 1: Product Inclusion - The newly added indications for Tyvyt® mean that all eight approved indications are now covered by medical insurance [1] - The directory also includes several recently launched new drugs targeting oncology and chronic diseases, such as China's first approved KRAS G12C inhibitor, Elunate® (fruquintinib), and the IGF-1R antibody drug, IBI310 (tislelizumab) [1] Group 2: Market Position - Currently, Innovent Biologics has a total of 17 innovative drugs on the market, with 12 of them included in the National Medical Insurance Directory [1]

Core Viewpoint - Innovent Biologics has successfully included seven innovative products in the updated 2025 National Reimbursement Drug List (NRDL), enhancing patient access to critical therapies for major diseases in China [1][2]. Product Summaries - **TYVYT® (sintilimab injection)**: Newly included indication for advanced endometrial cancer in combination with fruquintinib, addressing a significant treatment gap for patients with limited responses to traditional therapies [4][3]. - **SYCUME® (teprotumumab N01 injection)**: First approved IGF-1R antibody drug in China, newly listed for moderate-to-severe thyroid eye disease, significantly improving patient accessibility and affordability [6][5]. - **Limertinib**: Newly listed for treating advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC) and as a first-line treatment for specific EGFR mutations, offering enhanced penetration across the blood-brain barrier [9][8]. - **Dupert® (fulzerasib)**: Newly listed for advanced NSCLC patients with KRAS G12C mutation, providing a novel targeted therapy option [10]. - **DOVBLERON® (taletrectinib)**: Newly listed for locally advanced or metastatic ROS1-positive NSCLC, potentially offering a best-in-class therapy [12][11]. - **Retsevmo® (selpercatinib)**: Newly listed for various indications in NSCLC and thyroid cancer, being the first RET inhibitor approved globally [14][13]. - **Jaypirca® (pirtobrutinib)**: Newly listed for relapsed or refractory mantle cell lymphoma, addressing unmet needs for heavily treated patients [16][15]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing affordable, high-quality medicines for oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases [17]. The company has launched 17 products and has multiple assets in various stages of clinical trials [17].

Core Viewpoint - The company, Sinopharm (01801), announced the granting of stock options and restricted shares to certain recipients as part of its 2024 share plan, pending acceptance by the recipients [1] Group 1 - The company granted 15,000 stock options to 3 recipients [1] - The company also granted 148,200 restricted shares to 29 recipients [1] - The grants are subject to acceptance by the recipients [1]

智通财经APP讯，信达生物(01801)公布，于2025年12月5日，公司根据2024年股份计划的条款向3名承授 人授出1.5万份购股权，及向29名承授人授出14.82万股受限制股份，惟须待承授人接纳。 ...

格隆汇12月5日丨信达生物(01801.HK)公告，2025年12月5日，公司根据2024年股份计划的条款向3名承 授人授出1.5万份购股权，及向29名承授人授出148,200股受限制股份，惟须待承授人接纳。所有承授人 均为集团非关联雇员(非高级管理层)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） 授出購股權及受限制股份 本公告乃根據上市規則第17.06A、17.06B及17.06C條而作出。董事會宣佈，於 2025年12月5日，本公司根據2024年股份計劃的條款向3名承授人授出15,000份 購股權（「授出購股權」），及向29名承授人授出148,200股受限制股份（「授出受限 制股份」），惟須待承授人接納。所有承授人均為本集團非關聯僱員（非高級管理 層）。 授出購股權 授出購股權的詳情如下： 1 授出日期： 2025年12月5日 承授人數目： 3 授出購股權數目： 15,000 於授出購股權獲行使時將予認購 的新股份總數： 15,000 授出購股權的代價： 各承授人於接納授出的購股權時應支付1.00 港元 授出購股權的行使價： 每股股份93.62港元 購股權的行使價為每股股份 ...

消息面上，12月5日，信达生物发布公告，内容有关信达生物与武田制药(透过武田制药全资附属公司 Takeda Pharmaceuticals International AG)达成全球战略合作，许可、选择权及合作协议及股份发行协议 各自的所有先决条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行协 议于2025年12月4日完成。 于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 信达生物(01801)跌超3%，截至发稿，跌2.73%，报91港元，成交4.16亿港元。 ...

智通财经APP获悉，信达生物(01801)跌超3%，截至发稿，跌2.73%，报91港元，成交4.16亿港元。 消息面上，12月5日，信达生物发布公告，内容有关信达生物与武田制药(透过武田制药全资附属公司 Takeda Pharmaceuticals International AG)达成全球战略合作，许可、选择权及合作协议及股份发行协议 各自的所有先决条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行协 议于2025年12月4日完成。 于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 ...